Interview with Alex Godwood and Gabriel Glencross
The Introduction to Industry Training (ITIT) gives the delegates a taste of life across the pharmaceutical industry from early drug discovery to marketing, from CRO to Big Pharma and across the UK and continental Europe. The course aims to show the delegates the breadth and depth of work that goes on the industry and give them ideas of where they can get involved. PSI organized this course into 6 two-day sessions, each covering a stage of drug development and each hosted at a different company. The host company will give their unique perspective from experts in the field.
In this podcast, we talk about the following 9 important points:
- Overview of the ITIT course
- Who is the course aimed at
- What are the reasons to attend
- How the course keeps up with changes in the industry
- Where does the course fit in with the organization’s goals
- Why should a manager think about sending someone from their team on the course
- Which locations delegates can expect to visit
- What makes the course such a success
- From the delegates’ perspective, what are the benefits for the companies hosting the session
- When does the course run and when should delegates apply
Link to the ITIT course
If you would like to host a session, please contact:
Alex.Godwood@SoseiHeptares.com or firstname.lastname@example.org
Listen to this episode and learn from it!
About Alex Godwood
Alex Godwood is the current chairperson of the PSI ITIT committee and works at Sosei Heptares as the Director of Statistics. Alex has been working at Sosei Heptares for 2 years leading the statistical input into Translation Science and Early Clinical Development. Sosei Heptares is a biopharmaceutical company focused on the design and early development of new medicines originating from its proprietary GPCR-targeted StaR® technology and Structure-Based Drug Design platform capabilities.
Prior to Sosei Heptares Alex worked at AstraZeneca for 13 years, including 5 years in phase 3 oncology leading to the approval of FASLODEX 500mg and 8 years within the biologics organisation, MedImmune. At MedImmune, he worked as the project statistician for various programmes including a phase 2 programme for rheumatoid arthritis and a phase 3 programme for the orphan indication neuromyelitis optica. He also managed a team of statisticians working on respiratory, inflammation and autoimmune indications. Alex has also worked at GSK and Pfizer and studied at the universities of Warwick, Reading and Manchester.
About Gabriel Glencross
Gabriel Glencross is a Senior Associate Biostatistical Programmer at Amgen, a large multinational biopharmaceutical company, where he has worked since he joined the pharmaceutical industry in 2016.
He is part of the Statistical Programming Support team within Amgen’s Global Statistical Programming department, responsible for developing and maintaining SAS macros and other applications and utilities that are used across Amgen’s portfolio of life-changing medicines to improve the efficiency and reusability of the clinical study data analysis and reporting process. Gabriel has also had the experience of working as a study programmer on a range of late-phase oncology studies, developing and validating SDTM and ADaM datasets as well as tables and listings for the reporting of clinical trial data to support regulatory submissions, including a Phase 3b EU paediatric study for immune thrombocytopenic purpura. Gabriel attended the PSI ITIT course in 2017-2018.
Gabriel obtained a BSc in Mathematics and Statistics from the University of Bath, part of which included a placement year as a Data Analyst at the Higher Education Funding Council for England, where he developed his passion for SAS programming. In his spare time Gabriel is a keen runner; having completed over 100 5km parkruns he is (at the time of writing) training to run the Manchester Marathon in April 2020. His other hobbies include travelling, music, badminton, watching Arsenal FC and tackling new challenges.
Never miss an episode of The Effective Statistician
Join hundreds of your peers and subscribe to get our latest updates by email!